2020
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG
Binkley M, Rauf M, Milgrom S, Pinnix C, Tsang R, Dickinson M, Ng A, Roberts K, Gao S, Balogh A, Ricardi U, Levis M, Casulo C, Stolten M, Specht L, Plastaras J, Wright C, Kelsey C, Brady J, Mikhaeel N, Hoppe B, Terezakis S, Picardi M, Della Pepa R, Kirova Y, Akhtar S, Maghfoor I, Koenig J, Jackson C, Song E, Sehgal S, Advani R, Natkunam Y, Constine L, Eich H, Wirth A, Hoppe R. Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 2020, 135: 2365-2374. PMID: 32211877, DOI: 10.1182/blood.2019003877.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingNeoplasms, Radiation-InducedNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyProgression-Free SurvivalProportional Hazards ModelsRecurrenceRetrospective StudiesSalvage TherapySurvival AnalysisTreatment OutcomeYoung AdultConceptsNodular lymphocyte-predominant Hodgkin lymphomaProgression-free survivalOverall survivalImmunoarchitectural patternsAssociated with worse progression-free survivalFive-year PFSLymphocyte-predominant Hodgkin lymphomaProgression-free survival ratesStudy of adult patientsSingle-agent rituximabLarge-cell transformationStage I diseaseMedian follow-upMulticenter retrospective studyMulti-institutional studyHodgkin lymphomaI diseaseRT cohortHistological variantsMedian agePrimary managementRetrospective studyRituximabAdult patientsRadiotherapy
2017
Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome
Kann BH, Park HS, Yeboa DN, Aneja S, Girardi M, Foss FM, Roberts KB, Wilson LD. Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma & Leukemia 2017, 17: 520-526.e2. PMID: 28655598, DOI: 10.1016/j.clml.2017.05.017.Peer-Reviewed Original ResearchConceptsMF/SSOverall survivalSézary syndromeHazard ratioImproved survivalMycosis fungoidesPatient survivalHighest quintileLowest quintileTreatment volumeImproved overall survivalMultivariable Cox regressionNational Cancer DatabaseKaplan-Meier methodAnnual patient volumeNational database analysisLog-rank testContinuous variablesMedian followMultivariable analysisCox regressionOS survivalCancer DatabasePatientsPatient volume
2016
ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma.
Winkfield KM, Advani RH, Ballas LK, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Mendenhall NP, Metzger ML, Plastaras JP, Roberts KB, Shapiro R, Smith SM, Terezakis SA, Younes A, Constine LS. ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma. Oncology 2016, 30: 1099-103, 1106-8. PMID: 27987203, PMCID: PMC7440297.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansPractice Guidelines as TopicRecurrenceTransplantation, AutologousConceptsRecurrent Hodgkin lymphomaHodgkin's lymphomaAppropriateness CriteriaAutologous stem cell transplantationMedical literatureAppropriateness of imagingInnovative targeted therapiesCombined-modality therapyLow-dose therapyACR Appropriateness CriteriaEarly-stage diseaseStem cell transplantationMultidisciplinary expert panelRadiology Appropriateness CriteriaEvidence-based guidelinesSpecific clinical conditionsSpecific clinical scenariosCurrent medical literatureRecent medical literaturePeer-reviewed journalsRecurrent diseaseSalvage optionCell transplantationTargeted therapyClinical conditionsPostoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children
Kann BH, Park HS, Lester-Coll NH, Yeboa DN, Benitez V, Khan AJ, Bindra RS, Marks AM, Roberts KB. Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. JAMA Oncology 2016, 2: 1574-1581. PMID: 27491009, DOI: 10.1001/jamaoncol.2016.2547.Peer-Reviewed Original ResearchConceptsPostoperative radiotherapyOverall survivalMultivariable logistic regressionNational Cancer Data BaseLogistic regressionAdjuvant chemotherapy strategyLow facility volumeNational treatment patternsMultivariable Cox regressionLong-term morbidityYear of diagnosisDay of surgeryKaplan-Meier analysisNational database analysisPoor overall survivalLog-rank testYoung childrenAge 3Adjuvant chemotherapyRadiotherapy patternsRadiotherapy utilizationWorse survivalDistant metastasisMultivariable analysisTreatment patternsACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensityThe effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas
Stahl JM, Corso CD, Park HS, An Y, Rutter CE, Han D, Roberts KB. The effect of microscopic margin status on survival in adult retroperitoneal soft tissue sarcomas. European Journal Of Surgical Oncology 2016, 43: 168-174. PMID: 27335080, DOI: 10.1016/j.ejso.2016.05.031.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedPropensity ScoreRegistriesRetroperitoneal NeoplasmsRetrospective StudiesSarcomaSurvival RateUnited StatesConceptsSoft tissue sarcomasOverall survivalR1 resectionR0 resectionMargin statusNational Cancer Data BaseRetroperitoneal soft tissue sarcomaCox proportional hazards regressionPropensity scoreMultivariable logistic regression modelMedian overall survivalMicroscopic margin statusPre-operative RTReceipt of RTUnderwent R0 resectionSuperior overall survivalSmaller tumor sizeLow tumor gradeProportional hazards regressionLog-rank testRetroperitoneal soft tissueLogistic regression modelsLiposarcoma histologyR1 patientsRadiotherapy receipt
2013
For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery
Sen S, Soulos PR, Herrin J, Roberts KB, Yu JB, Lesnikoski BA, Ross JS, Krumholz HM, Gross CP. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Surgery 2013, 155: 776-788. PMID: 24787104, PMCID: PMC4008843, DOI: 10.1016/j.surg.2013.12.009.Peer-Reviewed Original ResearchConceptsHospital ownership statusBreast-conserving operationsBreast-conserving surgeryUse of brachytherapyRadiation therapyOperative careBreast cancerMedicare beneficiariesOverall useReceipt of brachytherapyAdjuvant radiation therapyInvasive breast cancerFemale Medicare beneficiariesGreater overall useYears of ageShort life expectancyRetrospective studyRT modalityProfit hospitalsExpensive modalityOlder womenBrachytherapy useBreast brachytherapyHospitalBrachytherapy
2012
Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal Of Clinical Oncology 2012, 30: 4302-4307. PMID: 23091103, PMCID: PMC3675700, DOI: 10.1200/jco.2012.43.5297.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsCombined Modality TherapyFemaleHumansMastectomy, SegmentalMedicareRetrospective StudiesUnited StatesConceptsWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsEarly-stage breast cancerNational treatment patternsPercent of patientsShort-term complicationsBreast-conserving surgeryNational Medicare populationComplication rateTreatment patternsAge 66Breast cancerReferral regionsMedicare populationPatterns of useComplicationsMedicare beneficiariesTreatment groupsClinical practiceBreast brachytherapyBrachytherapyInstrumental variable analysisAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2005
PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy
Roberts KB, Manus MP, Hicks RJ, Rischin D, Wirth A, Wright GM, Ball DL. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005, 47: 49-57. PMID: 15603854, DOI: 10.1016/j.lungcan.2004.06.014.Peer-Reviewed Original ResearchConceptsRadical radiotherapyExtensive diseaseNon-small cell lung cancerFluorodeoxyglucose positron emission tomographyRadical RTGood performance statusEvidence of diseaseAppropriateness of managementCell lung cancerEarly tumor progressionConcurrent chemotherapyIntrathoracic recurrenceThoracic recurrenceImpact of PETLimited diseaseProspective databaseTreatment intentPerformance statusRT doseSupportive careFurther patientsInflammatory changesUnexplained painClinical outcomesResidual tumor
2000
Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy
Elconin J, Roberts K, Rizzieri D, Vermont C, Clough R, Kim C, Dodge R, Prosnitz L. Radiation dose selection in Hodgkin’s disease patients with large mediastinal adenopathy treated with combined modality therapy. International Journal Of Radiation Oncology • Biology • Physics 2000, 48: 1097-1105. PMID: 11072168, DOI: 10.1016/s0360-3016(00)00695-7.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleHodgkin DiseaseHumansMaleMechlorethamineMediastinal NeoplasmsMiddle AgedNeoplasm StagingPrednisoneProcarbazineRadiotherapy DosageRetrospective StudiesTreatment FailureVinblastineVincristineConceptsLarge mediastinal adenopathyHodgkin's disease patientsComplete responseDisease patientsInduction chemotherapyInduction failureGallium scanMediastinal adenopathyModality therapyRT doseComplete clinical stagingLow-dose radiotherapyResidual radiographic abnormalitiesCycles of chemotherapyFailure-free survivalPhase III trialsPatterns of failureConsolidation radiationChemotherapy regimensCR patientsIII trialsOverall survivalClinical stagingHD patientsRadiographic abnormalities
1997
Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am
Chung J, Roberts K, Peschel R, Nath R, Pourang R, Kacinski B, Wilson L. Treatment of recurrent pelvic and selected primary gynecologic malignancies with 241Am. International Journal Of Cancer 1997, 5: 227-234. PMID: 9372545, DOI: 10.1002/(sici)1520-6823(1997)5:5<227::aid-roi3>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsRecurrent pelvic malignanciesPrimary gynecologic malignanciesPrimary radiotherapySurgical salvageMicroscopic diseasePelvic malignanciesPostoperative radiotherapyGynecologic malignanciesUltimate local control rateExternal beam radiation therapyGross primary tumorMedian patient ageLocal control rateTreatment of recurrentBeam radiation therapyMicroscopic residuumTreatment intentPatient ageSurgical resectionCurative therapyGynecologic tumorsGynecologic cancerControl ratePrimary tumorRadiation therapy
1996
Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy
Nath R, Roberts K. Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 977-979. PMID: 8960533, DOI: 10.1016/s0360-3016(96)00441-5.Peer-Reviewed Original ResearchMeSH KeywordsAngioplastyBrachytherapyCombined Modality TherapyCoronary DiseaseHumansRadiotherapy DosageRecurrence
1995
Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E, Doria R, Farber L, Roberts K, Cooper D. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study. The Cancer Journal 1995, 1: 267-73. PMID: 9166487.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolCombined Modality TherapyDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansMaleMechlorethamineMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryPrednisoneProcarbazineRemission InductionSalvage TherapyTime FactorsTreatment OutcomeVinblastineVincristineConceptsFailure-free survivalStage IV diseaseAdvanced Hodgkin's diseaseDisease-free survivalHodgkin's diseaseComplete remissionSecond malignanciesRadiation therapyLong-term disease-free survivalInvolved-field radiation therapyDurable second remissionsMOPP/ABVDRecurrent Hodgkin's diseaseInitial complete remissionCombined modality therapyMonths of chemotherapyLong-term resultsResults of treatmentSalvage therapySecond remissionInitial remissionUntreated patientsModality therapyOverall survivalChemotherapy program
1992
Combined chemotherapy and radiotherapy for Hodgkin's disease.
Prosnitz L, Roberts K. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992, 6: 113-28; discussion 131-2, 137. PMID: 1533138.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombined chemotherapyIntermediate-stage Hodgkin's diseaseSecond malignant neoplasmsStage Hodgkin's diseaseAdvanced Hodgkin's diseaseFrequency of relapsesSignificant adverse effectsConsolidation radiationComplete remissionConsolidation radiotherapyModality therapyCombination chemotherapyComplete responseField radiotherapyRelapse frequencyMalignant neoplasmsStandard treatmentLow doseChemotherapyRadiotherapyDiseaseRelapseAdverse effectsPatients